About Filoviruses
Filovirus infection refers to the infection caused by a group of viruses known as filoviruses (family Filoviridae). Filoviruses have genetic material called negative-sense RNA. This means their RNA must be copied into a usable form by the virus’s own enzymes once inside an infected cell before the virus can grow and reproduce. These viruses can cause severe illness, including death, in humans and non-human primates. The main filoviruses that cause disease in humans belong to the genera Orthoebolavirus (formerly Ebolavirus) and Orthomarburgvirus (Marburg virus and Ravn virus). Four orthoebolaviruses cause disease in people: Ebola virus, Sudan virus, Bundibugyo virus, and Taï Forest virus.
Filovirus infections can spread to people through contact with infected animals, such as fruit bats or non-human primates. Human-to-human transmission occurs through direct contact with the blood or body fluids of a person who is sick or has died from the disease, or with contaminated materials such as clothing, bedding, and needles. A person is contagious only once symptoms begin. These viruses do not spread through the air like influenza or COVID-19, and the risk to travelers and the general public is low.
The symptoms of filovirus infection can include high fever, fatigue, muscle and joint pain, headache, sore throat, nausea, vomiting, abdominal pain, diarrhea, and, in some people, unexplained bleeding. The incubation period for filovirus infections ranges from 2 to 21 days, and symptoms typically begin 8 to 10 days after exposure for Ebola disease.
Filovirus infections have high case fatality rates, reaching up to 90% depending on the virus, the outbreak, and the clinical care provided. Early supportive care improves survival. Vaccines and treatments are available only for Ebola disease caused by Ebola virus (Orthoebolavirus zairense). There are no approved vaccines or treatments for Sudan virus, Bundibugyo virus, Taï Forest virus, or Marburg virus, and developing and testing them is challenging because outbreaks are sporadic and unpredictable.
Filoviruses are transmitted through direct contact with the blood, organs, or other body fluids of infected humans or animals, or through contact with contaminated objects. Fruit bats are thought to be the natural reservoir for filoviruses, but the exact way the virus first passes from animals to people is not fully understood. Infection can cause severe disease in humans and non-human primates, leading to high fatality rates.
Risk factors for filovirus include:
- Occupation: People involved in artisan gold mining have a higher likelihood of exposure to filoviruses, possibly due to increased contact with bats.
- Gender: Males have been found to have a higher chance of testing positive for filovirus antibodies, which shows they were exposed to the virus in the past.
- Contact with suspect filovirus cases: People who have had contact with individuals suspected of having a filovirus infection are at an increased risk.
- Health care and caregiving: Health care workers and family members who care for a sick person without proper infection control and protective equipment have the highest risk of infection.
- Funeral and burial practices: Touching the body of someone who died of the disease can spread infection.
- Contact with animals: Handling or eating bats, primates, or raw meat from unknown animals in affected areas can lead to infection.
Avoiding contact with the blood and body fluids of people who are sick or have died, avoiding contact with bats, primates, and bushmeat in affected areas, using appropriate personal protective equipment, and following infection control measures can help reduce the risk of acquiring filovirus infection. A vaccine (Ervebo) is approved for the prevention of Ebola disease caused by Ebola virus (Orthoebolavirus zairense) only; U.S. adults 18 and older at potential risk of exposure are recommended to be vaccinated. Anyone returning from an area with an outbreak should monitor their health for 21 days.
Please consult a healthcare professional for personalized advice regarding the prevention and management of filovirus infection.
Symptoms usually begin 8 to 10 days after exposure (range 2 to 21 days). The most common early (“dry”) symptoms of filovirus infection include:
- Fever
- Chills
- Headache
- Muscle and body aches
- Fatigue
As the infection progresses, usually after about 5 days, the following (“wet”) symptoms and complications may occur:
- Gastrointestinal issues: Watery diarrhea, nausea, vomiting, and abdominal pain, which can cause severe fluid loss and dehydration
- Declining health: Getting weaker or sicker over time
- High levels of proinflammatory cytokines and chemokines: Proteins in the body that cause harmful inflammation
- Chest pain and confusion
- Hemorrhage: Unexplained bleeding inside or outside the body, which occurs in only some patients
- Shock: A life-threatening condition where organs don’t get enough blood or oxygen
- End organ failure: When major organs, like the liver or kidneys, stop working
It's important to note that variations in clinical presentations between individuals can complicate case identification. Additionally, fever may not be reported or observed in some cases, and the presence of hemorrhagic symptoms can vary widely. If you experience any of these symptoms or suspect a filovirus Infection, it is crucial to seek medical attention immediately.
To diagnose filovirus infection, the following examinations, tests, and procedures are commonly performed:
- Direct identification of viral particles, proteins, or specific RNA in blood samples can be done using tests such as electron microscopy (uses a powerful microscope to see the virus), histological techniques (examines tissue samples for signs of the virus), and immunofluorescence (uses glowing antibodies to detect the virus).
- Nucleic acid amplification tests (NAAT) to find the virus’s genetic material, called RNA. These tests include RT-PCR (reverse transcriptase polymerase chain reaction) and qRT-PCR (quantitative reverse transcriptase polymerase chain reaction). They work by making many copies of the virus’s RNA so even tiny amounts can be detected, which helps confirm the infection. RT-PCR is the standard test for people who are alive, but it may not detect the virus in the first few days after symptoms begin, so repeat testing may be needed.
- Rapid tests that detect viral proteins (antigens) can be used on swabs from deceased individuals to help confirm whether they were infected, supporting safe burials and outbreak control. Antibody tests can show past exposure.
To determine the severity of filovirus infection, additional examinations, tests, and procedures may include:
- Plasma viremia levels: Measuring the amount of virus in the blood (viremia) using nucleic acid tests (NATs), such as RT-PCR. Higher viremia levels can indicate a more severe infection and greater risk of complications.
- Imaging studies: Imaging, such as X-rays, may occasionally be used to look for complications, but it is not routinely needed to diagnose or grade filovirus infection.
- Organ function tests: Blood tests to evaluate liver, kidney, and other organ functions can help assess how severely the virus has affected the body.
It’s important to note that early symptoms are similar to more common illnesses such as malaria, typhoid fever, and influenza, so travel history and exposure risk are important. Suspected cases should be isolated and reported to public health authorities immediately. Diagnostic testing should be performed in specialized laboratories due to the high biohazard risk associated with filovirus infection. Always consult with your healthcare provider for accurate diagnosis and appropriate management.
The goals of treatment for filovirus Infection are to:
- Provide supportive care: Supportive care focuses on managing symptoms and complications to improve the patient’s overall well-being and survival. It includes intravenous fluids and electrolyte replacement, maintaining blood pressure, managing fever, providing pain relief, oxygen when needed, nutritional support, and treating secondary infections.
- Early diagnosis: Early diagnosis is crucial in order to start appropriate treatment promptly. Diagnostic tests, such as nucleic acid testing, can detect the virus once symptoms have begun, and people who receive early supportive care have better outcomes.
- Post-exposure prophylaxis (PEP) for Ebola virus (Orthoebolavirus zairense) only: Vaccination or antibody treatment may be considered for people who have been exposed to the virus but have not yet developed symptoms. Guidance on PEP should come from public health authorities.
- Monoclonal antibody (mAb) therapy: Monoclonal antibodies are laboratory-made antibodies that bind to the virus’s glycoprotein and prevent it from entering cells. Two mAb treatments, Inmazeb (a combination of three antibodies) and Ebanga (a single antibody), are approved by the U.S. FDA for Ebola disease caused by Ebola virus (Orthoebolavirus zairense). In a randomized trial in the Democratic Republic of the Congo, survival was higher in people who received either treatment. Their effectiveness has not been established for other filoviruses, such as Sudan virus, Bundibugyo virus, or Marburg virus.
- Combination therapy: Researchers are studying whether combining different drugs might work better together to treat filovirus infection. These combinations aim to lower the required dosage of individual drugs and reduce the chances of developing drug-resistant viral strains. Combination approaches are still investigational.
- Vaccination for prevention: The Ervebo vaccine is approved to prevent Ebola disease caused by Ebola virus (Orthoebolavirus zairense) only. It does not protect against other filoviruses, and no vaccine is currently approved for Marburg virus, Sudan virus, or Bundibugyo virus.
Medication dosing may be affected by many factors. Check with your health care professional about dosing for your individual situation. Side effects can occur. Check with your health care professional or read the information provided with your medication for side effect information.